FDA Approves First Drug Shown to Reduce Pancreatitis Risk…

FDA Approves First Drug Shown to Reduce Pancreatitis Risk in Severe Hypertriglyceridemia The US Food and Drug Administration (FDA) has approved olezarsen (Tryngolza) for the treatment of adults with severe hypertriglyceridemia, making it the first therapy demonstrated to reduce the risk of acute pancreatitis in this patient population. The approval represents an important advance for individuals with markedly elevated triglyceride levels, who are at increased risk of developing acute pancreatitis, a potentially life-threatening complication. What Is Severe Hypertriglyceridemia? Severe hypertriglyceridemia is characterized by markedly elevated blood triglyceride levels, typically 500 mg/dL or higher, with substantially increased pancreatitis risk at very high levels. Current management includes: Lifestyle modification Dietary changes Weight management Treatment of secondary